

# Alessandro Giunta

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8899540/publications.pdf>

Version: 2024-02-01

50  
papers

1,134  
citations

471509

17  
h-index

395702

33  
g-index

50  
all docs

50  
docs citations

50  
times ranked

1702  
citing authors

#	ARTICLE	IF	CITATIONS
1	Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic. <i>Dermatology and Therapy</i> , 2022, 12, 671-681.	3.0	5
2	Prevalence of Atherosclerosis in Psoriatic Patients Detected with Epi-aortic Color Doppler Ultrasound and Computed Tomography Angiography. <i>Dermatology Practical and Conceptual</i> , 2022, 12, e2022011.	0.9	1
3	Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity. <i>Archives of Dermatological Research</i> , 2021, 313, 431-437.	1.9	4
4	Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study. <i>Dermatologic Therapy</i> , 2021, 34, e14949.	1.7	4
5	Connective tissue nevus in Marfan Syndrome successfully treated with intralesional steroid injections. <i>Italian Journal of Dermatology and Venereology</i> , 2021, 156, 626-628.	0.2	0
6	A case of generalized pustular psoriasis and arthritis treated with ixekizumab. <i>Journal of Dermatological Treatment</i> , 2020, 31, 754-755.	2.2	4
7	Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series. <i>Postgraduate Medicine</i> , 2020, 132, 172-175.	2.0	4
8	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 119-128.	3.0	12
9	Ixekizumab in nail psoriasis. <i>Dermatologic Therapy</i> , 2020, 33, e13352.	1.7	1
10	Association between psoriasis and periodontitis, and efficacy of anti-TNF- $\alpha$ therapy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 508-511.	0.8	2
11	Early detection of IgH monoclonal rearrangement in follicular spicules of the nose preceding multiple myeloma diagnosis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 364-366.	0.8	0
12	Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 581-582.	0.8	2
13	The economic impact of biosimilars in Italy: a scenario analysis. <i>Global &amp; Regional Health Technology Assessment</i> , 2019, 2019, 228424031985802.	0.1	0
14	Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. <i>Postgraduate Medicine</i> , 2019, 131, 239-240.	2.0	7
15	Potential Role of Cytochrome c and Tryptase in Psoriasis and Psoriatic Arthritis Pathogenesis: Focus on Resistance to Apoptosis and Oxidative Stress. <i>Frontiers in Immunology</i> , 2018, 9, 2363.	4.8	46
16	Rapid, persistent, and simultaneous remission of urticaria and severe atopic dermatitis after treatment with omalizumab. <i>Journal of Dermatological Treatment</i> , 2018, 29, 2-4.	2.2	2
17	Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. <i>Frontiers in Immunology</i> , 2018, 9, 1936.	4.8	71
18	Long-term treatment with etanercept monotherapy in a hemodialyzed patient with moderate-to-severe plaque-type psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 882-884.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Morbid obesity and psoriasis: Disease remission after laparoscopic sleeve gastrectomy. <i>Obesity Research and Clinical Practice</i> , 2017, 11, 370-372.	1.8	4
20	Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1643-1651.	4.3	20
21	Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. <i>Psoriasis: Targets and Therapy</i> , 2017, Volume 7, 35-40.	2.2	9
22	Understanding the influence of patient demographics on disease severity, treatment strategy, and survival outcomes in merkel cell carcinoma: a surveillance, epidemiology, and end-results study. <i>Oncoscience</i> , 2017, 4, 106-114.	2.2	20
23	Granuloma annulare: a case treated with infliximab successfully. <i>Italian Journal of Dermatology and Venereology</i> , 2017, 152, 193-195.	0.2	1
24	Loss of CRABP-II Characterizes Human Skin Poorly Differentiated Squamous Cell Carcinomas and Favors DMBA/TPA-Induced Carcinogenesis. <i>Journal of Investigative Dermatology</i> , 2016, 136, 1255-1266.	0.7	11
25	UVA1 Laser in the Treatment of Vitiligo. <i>Photomedicine and Laser Surgery</i> , 2016, 34, 200-204.	2.0	8
26	Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice. <i>Journal of International Medical Research</i> , 2016, 44, 100-105.	1.0	9
27	S100A8/A9 in psoriatic plaques from patients with psoriatic arthritis. <i>Journal of International Medical Research</i> , 2016, 44, 33-37.	1.0	22
28	Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study. <i>Journal of International Medical Research</i> , 2016, 44, 72-75.	1.0	12
29	From patients'™ needs to treatment outcomes in psoriasis: Results from the 'psORRIDI'™ experience. <i>Journal of International Medical Research</i> , 2016, 44, 95-99.	1.0	5
30	Quality of life of psoriatic patients evaluated by a new psychometric assessment tool: PsoDisk. <i>European Journal of Dermatology</i> , 2015, 25, 64-69.	0.6	8
31	Treatment Adherence to Different Etanercept Regimens, Continuous vs. Intermittent, in Patients Affected by Plaque-Type Psoriasis. <i>Drug Development Research</i> , 2014, 75, S31-S34.	2.9	12
32	New topical treatments for psoriasis. <i>Expert Opinion on Pharmacotherapy</i> , 2014, 15, 461-470.	1.8	40
33	Emergence of Antinuclear Antibodies in Psoriatic Patients Treated with Infliximab: Personal Experience and Literature Review. <i>Drug Development Research</i> , 2014, 75, S61-3.	2.9	15
34	Clinical Markers Predictive of Primary Inefficacy: A 'Real Life' Retrospective Study in Psoriatic Patients Treated with Etanercept. <i>Drug Development Research</i> , 2014, 75, S27-S30.	2.9	6
35	UVA-1 Laser in the Treatment of Palmoplantar Pustular Psoriasis. <i>Photomedicine and Laser Surgery</i> , 2013, 31, 434-438.	2.0	26
36	Entecavir and Intermittent Etanercept Therapy in a Patient with Concurrent Hepatitis B Virus Infection and Psoriasis. <i>Acta Dermato-Venereologica</i> , 2013, 93, 373-374.	1.3	3

#	ARTICLE	IF	CITATIONS
37	Resolution with rituximab of localized scleroderma occurring during etanercept treatment in a patient with rheumatoid arthritis. <i>European Journal of Dermatology</i> , 2013, 23, 273-274.	0.6	26
38	Profile of certolizumab and its potential in the treatment of psoriatic arthritis. <i>Drug Design, Development and Therapy</i> , 2013, 7, 339.	4.3	25
39	Complete Resolution of Erythrodermic Psoriasis in an HIV and HCV Patient Unresponsive to Antipsoriatic Treatments after Highly Active Antiretroviral Therapy (Ritonavir, Atazanavir.) <i>TJ ETQq1 1 0.784314 rgB1.1 Overload 10 Tf 50</i>	0.784314	10
40	Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study. <i>Dermatology</i> , 2012, 225, 312-319.	2.1	68
41	Resolution of idiopathic recurrent pericarditis in a psoriatic arthritis patient treated with etanercept. <i>European Journal of Dermatology</i> , 2012, 22, 151-152.	0.6	2
42	Mobile Phones: A Role in Teaching Dermatology?. <i>Dermatology</i> , 2011, 222, 22-23.	2.1	6
43	A regulatory feedback loop involving p63 and IRF6 links the pathogenesis of 2 genetically different human ectodermal dysplasias. <i>Journal of Clinical Investigation</i> , 2010, 120, 1570-1577.	8.2	118
44	The tumor suppressor activity of IKK $\beta$ in stratified epithelia is exerted in part via the TGF- $\beta$ <sup>2</sup> antiproliferative pathway. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17091-17096.	7.1	59
45	Adalimumab for severe psoriasis and psoriatic arthritis: An open-label study in 30 patients previously treated with other biologics. <i>Journal of the American Academy of Dermatology</i> , 2007, 57, 269-275.	1.2	121
46	An Italian Study on Psoriasis and Depression. <i>Dermatology</i> , 2006, 212, 123-127.	2.1	210
47	Recent Patents and New Strategies in the Treatment of Psoriasis. <i>Recent Patents on Anti-infective Drug Discovery</i> , 2006, 1, 353-364.	0.8	5
48	Long-lasting remission of pemphigus vulgaris treated with rituximab. <i>Acta Dermato-Venereologica</i> , 2006, 86, 87-89.	1.3	28
49	Treatment of Hailey-Hailey disease with topical calcitriol. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 475-476.	1.2	29
50	Cutaneous body image in psoriasis: The role of attachment style and alexithymia. <i>Current Psychology</i> , 0, , 1.	2.8	0